Adherence to oral endocrine treatments in women with breast cancer: Can it be improved?

Breast Cancer Research and Treatment

Volumn 129, Issue 2, 2011, Pages 299-308

  Doggrell, Sheila A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Adherence; Adverse effects; Breast cancer; Interventions; Oral endocrine treatments

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CIMICIFUGA RACEMOSA EXTRACT; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; EXEMESTANE; GLUCOSAMINE; HORMONE; IBANDRONIC ACID; LETROZOLE; LUBRICATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE; VITAMIN D; ZOLEDRONIC ACID;

ACUPUNCTURE; AGE DISTRIBUTION; ARTHRALGIA; BONE DISEASE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE FREE SURVIVAL; DOCTOR PATIENT RELATION; DRUG COST; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH BELIEF; HEALTH CARE QUALITY; HOT FLUSH; HUMAN; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MENTAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NURSE; OSTEOLYSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACIST; PHARMACOGENETICS; PHYSICIAN; PRIORITY JOURNAL; RECURRENCE RISK; REMINDER SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SURVIVAL TIME; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VAGINAL DRYNESS;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; PROFESSIONAL-PATIENT RELATIONS; RISK FACTORS;

EID: 80052639734     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1578-z     Document Type: Review

References (66)

1. H Wildiers L Biganzoli J Fracheboud, et al. 2007 Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology Lancet Oncol 8 1101 1115 18054880 10.1016/S1470-2045(07) 70378-9 (Pubitemid 350182967)
2. GJ Morris S Naidu AK Topham, et al. 2007 Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution comparison compare with the National Cancer Institute's Surveillance, Epidemiology, and End Results database Cancer 110 876 884 17620276 10.1002/cncr.22836 (Pubitemid 47257667)
3. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group JF Forbes J Cuzick A Buzdar, et al. 2008 Effect of anastrozole and tamoxifen as adjuvant treatment of early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53 18083636 10.1016/S1470-2045(07)70385-6
4. P Hadji 2010 Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy Crit Rev Oncol Hematol 73 156 166 19299162 10.1016/j.critrevonc.2009.02.001
5. B Fisher J Constantino C Redmond, et al. 1989 A randomized clinical evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors N Engl J Med 320 479 484 2644532 10.1056/NEJM198902233200802 1:STN:280:DyaL1M7islChsw%3D%3D (Pubitemid 19062522)
6. B Fisher J Dignam J Bryant, et al. 1996 Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Natl Cancer Inst 88 1529 1542 8901851 10.1093/jnci/88.21.1529 1:CAS:528:DyaK2sXktlaltw%3D%3D (Pubitemid 26374506)
7. B Fisher J-H Jeong J Bryant, et al. 2004 Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Lancet 364 858 868 15351193 10.1016/S0140-6736(04)16981-X 1:CAS:528:DC%2BD2cXntlaqsL0%3D (Pubitemid 39221063)
8. C McCowan J Shearer PT Donnan, et al. 2008 Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 1763 1768 18985046 10.1038/sj.bjc.6604758 1:CAS:528:DC%2BD1cXhsVajtbrL
9. VO Dezentjé NJ van Blijderveen H Gelderblom, et al. 2010 Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer J Clin Oncol 28 2423 2429 20385997 10.1200/JCO.2009.25.0894
10. M Baum AU Budzar J Cuzick, et al. 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 2131 2139 12090977 10.1016/S0140-6736(02)09088-8 1:CAS:528:DC%2BD38XkslGhsLY%3D (Pubitemid 34694019)
11. PE Gross JN Ingle S Martino, et al. 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1791 1802
12. Breast International Group (BIG) 1-98 Collaborative Group B Thülimann A Keshaviah, et al. 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757 10.1056/NEJMoa052258 (Pubitemid 43016814)
13. AS Coates A Keshaviah B Thürlimann, et al. 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492 17200148 10.1200/JCO.2006.08.8617 1:CAS:528: DC%2BD2sXivF2mt7Y%3D (Pubitemid 350002953)
14. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 15014181 10.1056/NEJMoa040331 1:CAS:528:DC%2BD2cXitV2qtbc%3D (Pubitemid 38298988)
15. RC Coombes LS Kilburn CF Snowdon, et al. 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570 17307102 10.1016/S0140-6736(07)60200-1 1:CAS:528:DC%2BD2sXhvVGgsro%3D
16. CJ van de Velde D Rea C Seynaeve, et al. 2011 Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial Lancet 377 321 331 21247627 10.1016/S0140-6736(10)62312-4
17. S Demissie RA Silliman TL Lash 2001 Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women J Clin Oncol 19 322 328 11208822 1:CAS:528:DC%2BD3MXhtVektrk%3D (Pubitemid 32112842)
18. AH Partridge PS Wang EP Winer J Avorn 2003 Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer J Clin Oncol 21 602 606 12586795 10.1200/JCO.2003.07.071 1:CAS:528:DC%2BD2cXpsVGrtbs%3D (Pubitemid 46621892)
19. AK Fink J Gurwitz W Rakowski E Guadagnoli RA Silliman 2004 Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer J Clin Oncol 22 3309 3315 15310774 10.1200/JCO.2004.11.064 (Pubitemid 41103687)
20. TL Lash MP Fox JL Westrup AK Fink RA Sillman 2006 Adherence to tamoxifen over the five-year course Breast Cancer Res Treat 99 215 220 16541307 10.1007/s10549-006-9193-0 (Pubitemid 44268270)
21. TI Barron R Connolly K Bennett J Feely MJ Kennedy 2007 Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 832 839 17243168 10.1002/cncr.22485 1:CAS:528:DC%2BD2sXjsVKns7s%3D (Pubitemid 46333524)
22. C Owusu DS Buist TS Field, et al. 2008 Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer J Clin Oncol 26 549 555 18071188 10.1200/JCO.2006.10.1022 (Pubitemid 351264347)
23. AH Partridge A LaFountain E Mayer, et al. 2008 Adherence to initial anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 556 562 18180462 10.1200/JCO.2007.11.5451 1:CAS:528:DC%2BD1cXis1alsrc%3D (Pubitemid 351264348)
24. V Ziller M Kalder US Albert, et al. 2009 Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer Ann Oncol 20 431 436 19150950 10.1093/annonc/mdn646 1:STN:280:DC%2BD1M7mvVynsA%3D%3D
25. DL Hershman LH Kushi T Shao, et al. 2010 Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients J Clin Oncol 28 4120 4128 20585090 10.1200/JCO.2009.25. 9655
26. D Crevellari Z Sun AS Coates, et al. 2008 Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial J Clin Oncol 26 1972 1979 10.1200/JCO.2007.14.0459
27. U Güth DJ Huang A Schötzau, et al. 2008 Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer Br J Cancer 99 428 433 18665168 10.1038/sj.bjc.6604525
28. A Goldhirsch WC Wood RD Gelber, et al. 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 17675394 10.1093/annonc/mdm271 1:STN:280:DC%2BD2svlvVSkuw%3D%3D (Pubitemid 47244357)
29. SA Doggrell 2010 Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help Drugs Aging 27 239 254 20210369 10.2165/11532870-000000000-00000
30. JM Hoskins LA Carey HL McLeod 2009 CYP2D6 and tamoxifen: DNA matters in breast cancer Nat Rev Cancer 9 576 586 19629072 10.1038/nrc2683 1:CAS:528:DC%2BD1MXovFylt78%3D
31. W Schroth MP Goetz U Hamann, et al. 2009 Association between CYP2D6 polymorphisms and outcomes among women with early breast cancer treated with tamoxifen JAMA 302 1429 1436 19809024 10.1001/jama.2009.1420 1:CAS:528:DC%2BD1MXht1CksrjO
32. Pal S (2011) CYP2D6 testing falls short as predictor of adjuvant tamoxifen efficacy. http://www.cancernetwork.com/conference-reports/sabcs2010/ content/article/10165/1756542#. Accessed 5 May 2011
33. JM Rae MJ Sikora NL Henry, et al. 2009 Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients Pharmacogenomics J 9 258 264 19421167 10.1038/tpj.2009.14 1:CAS:528: DC%2BD1MXlsVKksbw%3D
34. CM Kelly DN Juurlink T Gomes, et al. 2010 Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population bases cohort study BMJ 340 C693 20142325 10.1136/bmj.c693
35. S Sehdev G Martin L Sideris W Lam S Brisson 2009 Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer Curr Oncol 16 Supplement 2 S14 S23 19672417
36. G Bertelli E Hall E Ireland, et al. 2010 Long-term endometrial effects in postmenopausal women with early breast cancer participation in the Intergroup Exemestane Study (IES)-a randomised controlled trial of exemestane versus continue tamoxifen after 2-3 years tamoxifen Ann Oncol 21 498 505 19717534 10.1093/annonc/mdp358 1:STN:280:DC%2BC3c7isVClsA%3D%3D
37. J Marsden 2002 Hormone-replacement therapy and breast cancer Lancet Oncol 3 303 311 12067808 10.1016/S1470-2045(02)00732-5 (Pubitemid 34546448)
38. JE Desmarais KJ Looper 2010 Managing menopausal symptoms and depression in tamoxifen uses: implications of drug and medicinal interactions Maturitas 67 296 308 20880642 10.1016/j.maturitas.2010.08.005 1:CAS:528:DC%2BC3cXhsV2jsL3F
39. C Buijs CH Mon PH Willesmse, et al. 2009 Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study Breast Cancer Res Treat 115 573 580 18670875 10.1007/s10549-008-0138-7 1:CAS:528:DC%2BD1MXmsVCrtL4%3D
40. Y Wengström 2008 Effectively nursing patients receiving aromatase inhibitor therapy Breast 17 227 238 18077168 10.1016/j.breast.2007.11.001
41. JW Carson KW Carson LS Porter FJ Keefe VL Seewaldt 2009 Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial Support Care Cancer 17 1301 1309 19214594 10.1007/s00520-009- 0587-5
42. JS Jacobson AB Troxel J Evans, et al. 2001 Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer J Clin Oncol 19 2739 2745 11352967 1:STN:280:DC%2BD3M3lsVOlsQ%3D%3D (Pubitemid 32441380)
43. J Hervik O Mjåland 2009 Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial Breast Cancer Res Treat 116 311 316 18839306 10.1007/s10549-008-0210-3
44. G Markopoulos E Tzoracoleftherakis A Polyschronis, et al. 2010 Management of anastrozole-induced bone loss in breast cancer with oral risedronate: results from the ARBI prospective clinical trial Breast Cancer Res 12 R24 20398352 10.1186/bcr2565
45. JE Lester D Dodwell OP Purohit, et al. 2008 Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer Clin Cancer Res 14 6336 6342 18829518 10.1158/1078-0432.CCR-07-5101 1:CAS:528:DC%2BD1cXhtF2nurbN
46. FJ Penning-van Beest WG Goettsch JA Erkens RM Herrings 2006 Determinants of persistence with bisphosphonates-a study in women with postmenopausal osteoporosis Clin Ther 28 236 242 16678644 10.1016/j.clinthera.2006.01.002 1:CAS:528:DC%2BD28Xmtl2ltrg%3D (Pubitemid 44287822)
47. JS McCombs B Thiebaud C McLaughlin-Miley J Shi 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 15207894 10.1016/j.maturitas.2004.02.005 1:CAS:528:DC%2BD2cXltVCiu7g%3D (Pubitemid 38781153)
48. DT Felson SR Cummings 2005 Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation Arthritis Rheum 52 2594 2598 16142740 10.1002/art.21364 1:CAS:528:DC%2BD2MXhtFeltrvK (Pubitemid 41369086)
49. JN Ingle DJ Schaid PE Goss, et al. 2010 Genome-wide associates and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors J Clin Oncol 10 4674 4682 10.1200/JCO.2010.28.5064
50. JJ Mao HI Su R Feng, et al. 2011 Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors Breast Cancer Res 13 R8 21251330 10.1186/bcr2813 1:CAS:528: DC%2BC3MXhvVKltLc%3D
51. Park IH, Lee Y-S, Lee KS et al (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol. doi: 10.1007/s00280-011-1615-y
52. KD Crew JL Capodice H Greenlee, et al. 2001 Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer J Clin Oncol 28 1154 1160 10.1200/JCO.2009.23.4708
53. G Xepapadakis P Ntasiou D Koronarchis, et al. 2010 New views on treatment of aromatase inhibitor induced arthralgia Breast 10 249 250 10.1016/j.breast.2010.03.031
54. NN Vattikuti C Ma A Rastelli, et al. 2010 High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer Breast J 16 606 616
55. D Prieto-Alhambra MK Javaid S Servitja, et al. 2011 Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study Breast Cancer Res Treat 125 869 878 20665105 10.1007/s10549-010-1075-9 1:CAS:528:DC%2BC3MXhtVels7o%3D
56. QJ Khan PS Reddy BF Kimler, et al. 2010 Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer Breast Cancer Res Treat 119 111 118 19655244 10.1007/s10549-009-0495-x 1:CAS:528: DC%2BD1MXhsFaqtr3P
57. L Briot M Tubiana-Hulin L Bastit I Kloos C Roux 2010 Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study Breast Cancer Res Treat 120 127 134 20035381 10.1007/s10549-009-0692-7 1:CAS:528:DC%2BC3cXntlalsQ%3D%3D
58. Switching to letrozole helps breast cancer patients with anastrozole-related rheumatologic symptoms. http://www.medicalnewstoday.com/ articles/174943.php. Accessed 2 Nov 2010
59. B Davidson V Vogel L Wickerham 2007 Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy J Support Oncol 5 139 143 17410813 (Pubitemid 46779582)
60. K Hartigan 2003 Patient education: the cornerstone of successful oral chemotherapy treatment Clin J Oncol Nurs 6 Suppl 21 24 10.1188/03.CJON.S6.21-24
61. C Miaskowski L Shockney RT Chlebowski 2008 Adherence to oral endocrine therapy for breast cancer: a nursing perspective Clin J Oncol Nurs 12 213 221 18390458 10.1188/08.CJON.213-221
62. FM Palmieri DL Barton 2007 Challenges of oral medications in patients with advanced breast cancer Semin Oncol Nurs 23 4 Suppl 2 S17 S22 18054678 10.1016/j.soncn.2007.10.004
63. A Kelly CR Agius 2006 Improving adherence to endocrine therapies: the role of advanced practice nurses Oncology 20 10 Suppl 50 54 18153980
64. CA Presant L Bosserman T Young, et al. 2007 Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients Clin Breast Cancer 10 775 778 10.3816/CBC.2007.n.038 (Pubitemid 350086121)
65. SY Barbour 2008 Caring for the treatment-experienced breast cancer patient: the pharmacist's role Am J Health Syst Pharm 65 10 Suppl 3 S16 S22 18463328 10.2146/ajhp080090 1:CAS:528:DC%2BD1cXmvVCgsL8%3D
66. Patient's anastrozole compliance to therapy programme (PACT). http://clinicaltrials.gov/ct2/show/NCT00555867. Accessed 2 Nov 2010